Comments*

 
  • Advances Against Aspergillosis I: Clinical Science

    Edited by Karl V. Clemons (California Institute for Medical Research, San Jose, California), Malcolm Richardson (Wythenshawe Hospital, Manchester, UK), and David S. Perlin (New Jersey Medical School-UMDNJ, Newark, New Jersey)
    Volume 1272, December 2012
    11 Papers

    Aspergillosis, the leading fungal cause of mortality in immunocompromised patients, presents a serious worldwide challenge—particularly in the face of increasing antifungal resistance. Bringing together the world’s leaders in the Aspergillus and aspergillosis fields to promote cross-disciplinary collaboration among clinicians, industry, and scientific experts, the “Advances Against Aspergillosis” conference was held January 26–28, 2012 in Istanbul, Turkey. Among the topics included are the application of diagnostic markers to invasive aspergillosis in children, risk stratification for invasive aspergillosis in immunocompromised patients, use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis, immune regulation in idiopathic bronchiectasis, and management of chronic pulmonary aspergillosis.

    Table of contents
    EmailPrint